Advanced in Follicular Lymphoma

Walter Mingrone

Olten, SO, CH 
Advanced in Follicular Lymphoma
Olten, SO, CH 
OverviewLocationsClinical Research

Overview

Walter Mingrone practices in Olten, Switzerland. Mr. Mingrone is rated as an Advanced expert by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Follicular Lymphoma, Testicular Cancer, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and Orchiectomy.

His clinical research consists of co-authoring 21 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 1 clinical trial in the study of Follicular Lymphoma.

Gender
Male

Locations

Olten, SO, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). A Multicenter Single Arm Open Label Phase II Trial.
Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). A Multicenter Single Arm Open Label Phase II Trial.
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Radiation
Study Drugs: Durvalumab, Carboplatin, Etoposide
Study Phase: Phase 2
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Enrollment Status: Terminated
Publish Date: May 16, 2025
Intervention Type: Drug
Study Drug: Aspirin
Study Phase: Phase 3
Assessing a Circulating Tumor (ctDNA) and Positron Emission Tomography (PET)-Oriented Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL). A Multicenter, Open-label, Phase II Trial.
Assessing a Circulating Tumor (ctDNA) and Positron Emission Tomography (PET)-Oriented Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL). A Multicenter, Open-label, Phase II Trial.
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drug: Acalabrutinib
Study Phase: Phase 2
Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma
Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma
Enrollment Status: Terminated
Publish Date: February 13, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 2
IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2024
Intervention Type: Radiation, Other
Study Phase: Not Applicable
Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.
Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drugs: Ibrutinib, Rituximab
Study Phase: Phase 2
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone (IMPROVE TRIAL): A Randomized, Open Label, Phase II Trial
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone (IMPROVE TRIAL): A Randomized, Open Label, Phase II Trial
Enrollment Status: Terminated
Publish Date: June 27, 2023
Intervention Type: Drug
Study Drugs: Enzalutamide, Metformin
Study Phase: Phase 2
Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy. A Multicenter Open Label Randomized Controlled Trial
Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy. A Multicenter Open Label Randomized Controlled Trial
Enrollment Status: Terminated
Publish Date: November 07, 2022
Intervention Type: Other
Study Phase: Not Applicable
View 7 Less Clinical Trials

21 Total Publications

Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update.
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update.
Journal: Blood advances
Published: September 17, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mingrone's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile